Influence of acute and chronic administration of benzylamine on glucose tolerance in diabetic and obese mice fed on very high-fat diet.
The combination of vanadate plus benzylamine has been reported to stimulate glucose transport in rodent adipocytes and to mimic other insulin actions in diverse studies. However, benzylamine alone activates glucose uptake in human fat cells and increases glucose tolerance in rabbits. The aim of this work was to unravel the benzylamine antihyperglycemic action and to test whether its chronic oral administration could restore the defective glucose handling of mice rendered slightly obese and diabetic by very high-fat diet (VHFD). When VHFD mice were i.p. injected with benzylamine at 0.7 to 700 micromol/kg before glucose tolerance test, they exhibited reduced hyperglycemic response without alteration of insulin secretion. Whole body glucose turnover, as assessed by the glucose isotopic dilution technique, was unchanged in mice perfused with benzylamine (total dose of 75 micromol/kg). However, their in vivo glycogen synthesis rate was increased. Benzylamine appeared therefore to directly facilitate glucose utilisation in peripheral tissues. When given chronically at 2000 or 4000 micromol/kg/d in drinking water, benzylamine elicited a slight reduction of water consumption but did not change body weight or adiposity and did not modify oxidative stress markers. Benzylamine treatment improved glucose tolerance but failed to normalize the elevated glucose fasting plasma levels of VHFD mice. There was no influence of benzylamine ingestion on lipolytic activity, basal and insulin-stimulated glucose uptake, and on inflammatory adipokine expression in adipocytes. The improvement of glucose tolerance and the lack of adverse effects on adipocyte metabolism, reported here in VHFD mice allow to consider orally given benzylamine as a potential antidiabetic strategy which deserves to be further studied in other diabetic models.
Iffiú-Soltész'
Z
Z
INSERM U858, IFR 31 Rangueil, I2MR, equipe 3, Université Toulouse III Paul-Sabatier, Toulouse, France.
Prévot
D
D
Grés
S
S
Bour
S
S
Szökö
E
E
Knauf
C
C
Burcelin
R
R
Fernández-Quintela
A
A
Lomba
A
A
Milagro
F I
FI
Carpéné
C
C
D017667:Adipocytes / Q000378:metabolism; D000818:Animals; D001596:Benzylamines / Q000008:administration & dosage* / Q000494:pharmacology; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000378:metabolism*; D004041:Dietary Fats / Q000008:administration & dosage; D005947:Glucose / Q000378:metabolism*; D005951:Glucose Tolerance Test; D006949:Hyperlipidemias / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009765:Obesity / Q000150:complications / Q000378:metabolism; D018384:Oxidative Stress
D001596:Benzylamines; D004041:Dietary Fats; D007004:Hypoglycemic Agents; C030796:benzylamine; D005947:Glucose